BR112016030375A8 - uso de um composto no tratamento ou melhora da enxaqueca, no tratamento, supressão e/ou prevenção da depressão cortical e no tratamento ou melhora de uma lesão cerebral traumática - Google Patents

uso de um composto no tratamento ou melhora da enxaqueca, no tratamento, supressão e/ou prevenção da depressão cortical e no tratamento ou melhora de uma lesão cerebral traumática

Info

Publication number
BR112016030375A8
BR112016030375A8 BR112016030375A BR112016030375A BR112016030375A8 BR 112016030375 A8 BR112016030375 A8 BR 112016030375A8 BR 112016030375 A BR112016030375 A BR 112016030375A BR 112016030375 A BR112016030375 A BR 112016030375A BR 112016030375 A8 BR112016030375 A8 BR 112016030375A8
Authority
BR
Brazil
Prior art keywords
migraine
treatment
methods
amelioration
treating
Prior art date
Application number
BR112016030375A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016030375A2 (pt
Inventor
Joseph R Moskal
Patric Stanton
Original Assignee
Univ Northwestern
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern, Naurex Inc filed Critical Univ Northwestern
Publication of BR112016030375A2 publication Critical patent/BR112016030375A2/pt
Publication of BR112016030375A8 publication Critical patent/BR112016030375A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112016030375A 2014-06-23 2015-06-23 uso de um composto no tratamento ou melhora da enxaqueca, no tratamento, supressão e/ou prevenção da depressão cortical e no tratamento ou melhora de uma lesão cerebral traumática BR112016030375A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015727P 2014-06-23 2014-06-23
US201562109386P 2015-01-29 2015-01-29
PCT/US2015/037177 WO2015200322A1 (en) 2014-06-23 2015-06-23 Methods of treating or ameliorating migraine

Publications (2)

Publication Number Publication Date
BR112016030375A2 BR112016030375A2 (pt) 2017-08-15
BR112016030375A8 true BR112016030375A8 (pt) 2021-07-13

Family

ID=54938737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030375A BR112016030375A8 (pt) 2014-06-23 2015-06-23 uso de um composto no tratamento ou melhora da enxaqueca, no tratamento, supressão e/ou prevenção da depressão cortical e no tratamento ou melhora de uma lesão cerebral traumática

Country Status (10)

Country Link
EP (1) EP3157943A4 (https=)
JP (2) JP6688748B2 (https=)
KR (1) KR20170018072A (https=)
CN (1) CN106661085A (https=)
AU (1) AU2015280108B2 (https=)
BR (1) BR112016030375A8 (https=)
CA (1) CA2953170A1 (https=)
MX (1) MX2016017388A (https=)
RU (1) RU2721401C2 (https=)
WO (1) WO2015200322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7476229B2 (ja) * 2019-04-15 2024-04-30 フェリン・ファーマシューティカルズ・インコーポレイテッド 片頭痛の治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006468A1 (en) * 1993-09-01 1995-03-09 Smithkline Beecham Corporation Method for treating migraine headaches
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
EP1337559A2 (en) * 2000-11-17 2003-08-27 Bayer Ag Regulation of human nmda receptor
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
NZ590793A (en) * 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
WO2011003064A2 (en) * 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
CN105037492A (zh) * 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US20150253305A1 (en) * 2012-10-12 2015-09-10 Northwestern University Methods of identifying compounds for treating depression and other related diseases

Also Published As

Publication number Publication date
BR112016030375A2 (pt) 2017-08-15
JP2017519778A (ja) 2017-07-20
CA2953170A1 (en) 2015-12-30
MX2016017388A (es) 2018-02-19
RU2017101410A3 (https=) 2019-01-21
CN106661085A (zh) 2017-05-10
AU2015280108B2 (en) 2019-11-28
KR20170018072A (ko) 2017-02-15
RU2017101410A (ru) 2018-07-24
WO2015200322A1 (en) 2015-12-30
JP2020114863A (ja) 2020-07-30
AU2015280108A1 (en) 2017-01-19
EP3157943A4 (en) 2018-01-24
RU2721401C2 (ru) 2020-05-19
EP3157943A1 (en) 2017-04-26
JP6688748B2 (ja) 2020-04-28

Similar Documents

Publication Publication Date Title
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
MX2018013003A (es) Oligonucleotidos para tratar una enfermedad ocular.
DOP2017000268A (es) Metodos y kits para tratar depresion
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
BR112014010803A2 (pt) método de tratamento
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
WO2014190163A3 (en) Combination therapy for mds
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX382757B (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MX2016008108A (es) Angiotensina ii sola o en combinacion para el tratamiento de hipotension.
BR112016017886A8 (pt) grelina ou variantes ou derivados da mesma, e, usos da grelina
MX2020004497A (es) Administracion oral de analogos del peptido glp-1.
CL2019000625A1 (es) Combinación de agonistas de fxr.
WO2016134257A8 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2676 DE 19-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.